Telo Genomics Corp (TELO : TSX-V)
Common Stock
$0.04
CAD
+0.00 (%)
Last updated: 2026-06-25
TELO
Telo Genomics Corp
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-18.18%
1 Month
-30.77%
YTD
-10.00%
Key Statistics
Market Cap
$4.52M
52W High
$0.12
52W Low
$0.04
P/E Ratio
-
50 Day MA
$0.06
200 Day MA
$0.06
Beta
0.18
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/25/2026 | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 | 0 |
| 6/24/2026 | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 | 4,223 |
| 6/23/2026 | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 | 123,600 |
| 6/22/2026 | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 | 1,019 |
| 6/19/2026 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 79,000 |
| 6/18/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 0 |
| 6/17/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 0 |
| 6/16/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 58,000 |
| 6/15/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 0 |
| 6/12/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 0 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELO's historical volatility
30-Day Vol
133.8%
Annualized
90-Day Vol
112.2%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.05
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.05 | C$0.03 – C$0.07 |
| 60 trading days | C$0.05 | C$0.02 – C$0.09 |
| 90 trading days | C$0.05 | C$0.02 – C$0.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-1.87M
- Profit Margin
- 0.00%
- ROE (TTM)
- -4675.28%
- EPS (Diluted)
- -0.03
- Book Value
- -0.01
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About TELO
Articles Featuring TELO.V
Latest articles and analysis covering TELO.V
